Interpace Biosciences, Inc. (IDXG)
USD 1.13
(-9.6%)
USD 1.13
(-9.6%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 20.23 Million USD | -8.33% |
| 2022 | 22.07 Million USD | -25.64% |
| 2021 | 29.68 Million USD | -20.38% |
| 2020 | 37.28 Million USD | 16.05% |
| 2019 | 32.12 Million USD | 44.08% |
| 2018 | 22.29 Million USD | 9.11% |
| 2017 | 20.43 Million USD | -4.44% |
| 2016 | 21.38 Million USD | -35.95% |
| 2015 | 33.38 Million USD | 11.56% |
| 2014 | 29.92 Million USD | 4.32% |
| 2013 | 28.68 Million USD | 2.94% |
| 2012 | 27.86 Million USD | -25.03% |
| 2011 | 37.17 Million USD | 1.82% |
| 2010 | 36.5 Million USD | -25.09% |
| 2009 | 48.73 Million USD | 22.76% |
| 2008 | 39.7 Million USD | -13.49% |
| 2007 | 45.89 Million USD | -3.19% |
| 2006 | 47.4 Million USD | -46.63% |
| 2005 | 88.82 Million USD | 39.57% |
| 2004 | 63.63 Million USD | -8.23% |
| 2003 | 69.34 Million USD | -9.74% |
| 2002 | 76.83 Million USD | -37.57% |
| 2001 | 123.07 Million USD | 66.94% |
| 2000 | 73.72 Million USD | 143.31% |
| 1999 | 30.3 Million USD | 113.38% |
| 1998 | 14.2 Million USD | 77.5% |
| 1997 | 8 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.19 Million USD | 8.5% |
| 2024 Q2 | 5.17 Million USD | -0.44% |
| 2024 Q3 | 5.6 Million USD | 8.25% |
| 2023 Q4 | 4.79 Million USD | 0.4% |
| 2023 Q2 | 6 Million USD | 13.2% |
| 2023 Q3 | 4.77 Million USD | -20.52% |
| 2023 Q1 | 5.3 Million USD | 8.91% |
| 2023 FY | 20.23 Million USD | -8.33% |
| 2022 Q4 | 4.86 Million USD | -11.67% |
| 2022 FY | 22.07 Million USD | -25.64% |
| 2022 Q1 | 6.94 Million USD | -9.23% |
| 2022 Q2 | 7.48 Million USD | 7.81% |
| 2022 Q3 | 5.51 Million USD | -26.34% |
| 2021 Q1 | 7.07 Million USD | -38.73% |
| 2021 FY | 29.68 Million USD | -20.38% |
| 2021 Q3 | 7.26 Million USD | -4.92% |
| 2021 Q2 | 7.63 Million USD | 7.9% |
| 2021 Q4 | 7.64 Million USD | 5.3% |
| 2020 Q2 | 7.28 Million USD | -20.89% |
| 2020 Q4 | 11.55 Million USD | 27.54% |
| 2020 Q3 | 9.05 Million USD | 24.37% |
| 2020 Q1 | 9.2 Million USD | -3.6% |
| 2020 FY | 37.28 Million USD | 16.05% |
| 2019 FY | 32.12 Million USD | 44.08% |
| 2019 Q1 | 6.66 Million USD | 7.26% |
| 2019 Q2 | 7.2 Million USD | 8.15% |
| 2019 Q3 | 9.1 Million USD | 26.28% |
| 2019 Q4 | 9.55 Million USD | 4.96% |
| 2018 Q2 | 5.15 Million USD | -5.93% |
| 2018 FY | 22.29 Million USD | 9.11% |
| 2018 Q4 | 6.21 Million USD | 13.9% |
| 2018 Q3 | 5.45 Million USD | 5.88% |
| 2018 Q1 | 5.47 Million USD | -6.46% |
| 2017 FY | 20.43 Million USD | -4.44% |
| 2017 Q4 | 5.85 Million USD | 11.99% |
| 2017 Q3 | 5.22 Million USD | -6.21% |
| 2017 Q1 | 3.77 Million USD | -28.66% |
| 2017 Q2 | 5.57 Million USD | 47.58% |
| 2016 Q2 | 4.66 Million USD | -17.54% |
| 2016 Q1 | 5.65 Million USD | 1479.51% |
| 2016 Q4 | 5.29 Million USD | -8.23% |
| 2016 FY | 21.38 Million USD | -35.95% |
| 2016 Q3 | 5.76 Million USD | 23.69% |
| 2015 Q4 | -410 Thousand USD | -103.65% |
| 2015 FY | 33.38 Million USD | 11.56% |
| 2015 Q1 | 10.52 Million USD | 30.82% |
| 2015 Q2 | 12.03 Million USD | 14.32% |
| 2015 Q3 | 11.23 Million USD | -6.66% |
| 2014 FY | 29.92 Million USD | 4.32% |
| 2014 Q3 | 7.95 Million USD | 8.81% |
| 2014 Q4 | 8.04 Million USD | 1.12% |
| 2014 Q2 | 7.31 Million USD | 10.72% |
| 2014 Q1 | 6.6 Million USD | -17.66% |
| 2013 Q3 | 6.74 Million USD | -12.32% |
| 2013 Q1 | 6.22 Million USD | -7.18% |
| 2013 Q2 | 7.69 Million USD | 23.73% |
| 2013 Q4 | 8.02 Million USD | 18.89% |
| 2013 FY | 28.68 Million USD | 2.94% |
| 2012 Q2 | 6.88 Million USD | -9.24% |
| 2012 Q1 | 7.58 Million USD | -14.44% |
| 2012 Q4 | 6.7 Million USD | 0.09% |
| 2012 FY | 27.86 Million USD | -25.03% |
| 2012 Q3 | 6.69 Million USD | -2.77% |
| 2011 Q3 | 8.14 Million USD | -15.71% |
| 2011 Q2 | 9.65 Million USD | -8.08% |
| 2011 FY | 37.17 Million USD | 1.82% |
| 2011 Q4 | 8.86 Million USD | 8.92% |
| 2011 Q1 | 10.5 Million USD | -12.7% |
| 2010 Q4 | 12.03 Million USD | 49.26% |
| 2010 Q1 | 8.63 Million USD | -43.18% |
| 2010 FY | 36.5 Million USD | -25.09% |
| 2010 Q2 | 8.87 Million USD | 2.8% |
| 2010 Q3 | 8.06 Million USD | -9.18% |
| 2009 Q1 | 10.55 Million USD | 35.18% |
| 2009 Q2 | 11.56 Million USD | 9.6% |
| 2009 FY | 48.73 Million USD | 22.76% |
| 2009 Q3 | 11.42 Million USD | -1.2% |
| 2009 Q4 | 15.19 Million USD | 33.03% |
| 2008 Q1 | 10.4 Million USD | -17.56% |
| 2008 Q4 | 7.8 Million USD | -21.96% |
| 2008 FY | 39.7 Million USD | -13.49% |
| 2008 Q3 | 10 Million USD | -12.96% |
| 2008 Q2 | 11.49 Million USD | 10.41% |
| 2007 Q2 | 11.03 Million USD | -1.6% |
| 2007 Q1 | 11.21 Million USD | -0.48% |
| 2007 FY | 45.89 Million USD | -3.19% |
| 2007 Q4 | 12.62 Million USD | 14.59% |
| 2007 Q3 | 11.01 Million USD | -0.2% |
| 2006 Q3 | 13.01 Million USD | 9.17% |
| 2006 Q4 | 11.27 Million USD | -13.39% |
| 2006 Q2 | 11.92 Million USD | 6.27% |
| 2006 Q1 | 11.21 Million USD | -66.92% |
| 2006 FY | 47.4 Million USD | -46.63% |
| 2005 Q1 | 18.81 Million USD | 4.54% |
| 2005 Q2 | 15.28 Million USD | -18.79% |
| 2005 Q3 | 20.81 Million USD | 36.16% |
| 2005 Q4 | 33.91 Million USD | 62.96% |
| 2005 FY | 88.82 Million USD | 39.57% |
| 2004 Q1 | 16.7 Million USD | -13.17% |
| 2004 Q3 | 15.35 Million USD | 13.03% |
| 2004 FY | 63.63 Million USD | -8.23% |
| 2004 Q4 | 18 Million USD | 17.27% |
| 2004 Q2 | 13.58 Million USD | -18.71% |
| 2003 FY | 69.34 Million USD | -9.74% |
| 2003 Q2 | 16.32 Million USD | -2.84% |
| 2003 Q4 | 19.24 Million USD | 13.36% |
| 2003 Q3 | 16.97 Million USD | 3.94% |
| 2003 Q1 | 16.8 Million USD | -46.5% |
| 2002 Q4 | 31.41 Million USD | 68.99% |
| 2002 Q1 | 11.08 Million USD | -43.98% |
| 2002 Q2 | 15.74 Million USD | 42.04% |
| 2002 Q3 | 18.59 Million USD | 18.08% |
| 2002 FY | 76.83 Million USD | -37.57% |
| 2001 Q2 | 32.7 Million USD | -10.98% |
| 2001 Q4 | 19.78 Million USD | -41.53% |
| 2001 Q1 | 36.74 Million USD | 0.6% |
| 2001 Q3 | 33.84 Million USD | 3.47% |
| 2001 FY | 123.07 Million USD | 66.94% |
| 2000 FY | 73.72 Million USD | 143.31% |
| 2000 Q4 | 36.52 Million USD | 157.61% |
| 2000 Q3 | 14.17 Million USD | 38.48% |
| 2000 Q2 | 10.23 Million USD | -19.91% |
| 2000 Q1 | 12.78 Million USD | 54.03% |
| 1999 Q1 | 4.7 Million USD | 6.82% |
| 1999 Q2 | 7.8 Million USD | 65.96% |
| 1999 Q3 | 7.3 Million USD | -6.41% |
| 1999 FY | 30.3 Million USD | 113.38% |
| 1999 Q4 | 8.3 Million USD | 13.7% |
| 1998 Q2 | 3.2 Million USD | 433.33% |
| 1998 FY | 14.2 Million USD | 77.5% |
| 1998 Q3 | 4 Million USD | 25.0% |
| 1998 Q4 | 4.4 Million USD | 10.0% |
| 1998 Q1 | 600 Thousand USD | 101.15% |
| 1997 Q4 | -52.3 Million USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 FY | 8 Million USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | -1828.694% |
| Arrayit Corporation | 6.19 Million USD | -226.45% |
| Atlantic International Corp. | 5.57 Million USD | -262.693% |
| Biocept, Inc. | 29.4 Million USD | 31.186% |
| Bioqual, Inc. | 7.44 Million USD | -171.615% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | -2520.243% |
| DermTech, Inc. | 104.01 Million USD | 80.549% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | 87.849% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | 10.572% |
| iMD Companies, Inc. | 151.8 Thousand USD | -13227.273% |
| IDenta Corp. | 662.97 Thousand USD | -2951.699% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -51935.699% |
| InVitro International | 661.32 Thousand USD | -2959.317% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | -185.038% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -34715.529% |
| Medical Imaging Corp. | 1.91 Million USD | -958.068% |
| NovelStem International Corp. | 3.53 Million USD | -471.881% |
| Optigenex Inc. | 1.28 Million USD | -1470.967% |
| PharmChem, Inc. | 2.93 Million USD | -590.222% |
| Proteome Sciences plc | 3.26 Million USD | -519.094% |
| Response Genetics, Inc | 25.31 Million USD | 20.092% |
| Rennova Health, Inc. | 7.67 Million USD | -163.514% |
| RushNet, Inc. | 1.78 Million USD | -1030.709% |
| ScreenPro Security Inc. | 3.23 Million USD | -524.654% |
| Stella Diagnostics Inc. | 11.42 Million USD | -77.055% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | -175.527% |
| Todos Medical Ltd. | 14.05 Million USD | -43.918% |